Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer Q4 net profit...

    Pfizer Q4 net profit falls 22% to Rs 68 cr

    Written by Ruby Khatun Khatun Published On 2017-05-08T17:47:12+05:30  |  Updated On 8 May 2017 5:47 PM IST
    Pfizer Q4 net profit falls 22% to Rs 68 cr

    New Delhi: Drug firm Pfizer reported a 21.98 per cent dip in its standalone net profit at Rs 68.04 crore for the fourth quarter ended March 31, 2017. The company had posted a net profit of Rs 87.21 crore for the corresponding period of the previous fiscal, Pfizer Ltd said in a filing to BSE.


    Standalone total income of the company for the quarter under consideration stood at Rs 481.97 crore as against Rs 563.57 crore in the same period a year ago.


    For the fiscal year ended March 31, the net profit of the company stood at Rs 336.78 crore. It was Rs 304.99 crore during the preceding fiscal.


    Total income of the company stood at Rs 2,143.09 crore for the fiscal year ended March 31.


    Its total income during 2015-16 fiscal was at Rs 2,180.75 crore.


    The board of directors of the company has recommended a normal dividend of Rs 15 per equity share of Rs 10 each and a special dividend of Rs 5 per share of Rs 10 each on account of exceptional income during the year for the financial year ended March 31, Pfizer said. PTI AKT ABI

    21.98 per cent dipfourth quarterLossnet profitnormal dividendPfizerRs 68.04 crore
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok